Skip to Content

Join the 'Psoriasis' group to help and get support from people like you.

Psoriasis News

Related terms: Erythrodermic Psoriasis, Guttate Psoriasis, Inverse Psoriasis, Palmo-plantar Psoriasis, Psoriasis vulgaris, Pustular Psoriasis

Psoriasis Linked to Higher Risk of Depression

Posted 15 days ago by

THURSDAY, Aug. 20, 2015 – People with psoriasis may be twice as likely to experience depression as those without the common skin condition, regardless of its severity, a new study suggests. "Psoriasis in general is a pretty visible disease," said study author Dr. Roger Ho, an assistant professor of dermatology at New York University School of Medicine in New York City. "Psoriasis patients are fearful of the public's stigmatization of this visible disease and are worried about how people who are unfamiliar with the disease may perceive them or interact with them." Genetic or biologic factors may also play a role in the link between depression and psoriasis, which requires more research, he said. Either way, the findings mean that all individuals with psoriasis could benefit from screening for depression, Ho said, and their friends and family members should be aware of the connection as ... Read more

Related support groups: Depression, Lexapro, Zoloft, Cymbalta, Wellbutrin, Effexor, Prozac, Celexa, Paxil, Trazodone, Citalopram, Pristiq, Sertraline, Viibryd, Amitriptyline, Bupropion, Effexor XR, Fluoxetine, Major Depressive Disorder, Venlafaxine

Psoriasis Drug May Help Preserve Pancreas Cells in Type 1 Diabetes

Posted 21 Jul 2015 by

TUESDAY, July 21, 2015 – Taking two 12-week courses of alefacept – a drug already approved to treat the skin condition psoriasis – may help people with newly diagnosed type 1 diabetes preserve some function in the beta cells in the pancreas, a new study suggests. People taking the drug needed about 25 percent less insulin, and they had about half the rate of major low blood sugar episodes (hypoglycemia) compared to those who took a placebo, the study revealed. "This is the first time that documented rates of hypoglycemia – using standardized home glucometers in all patients – have shown a reduction in major hypoglycemia events following an immune intervention in new-onset [type 1 diabetes] patients," lead researcher Dr. Mario Ehlers, of the Immune Tolerance Network, said in a network news release. "This is important because frequent hypoglycemia is a common and serious complication ... Read more

Related support groups: Psoriasis, Diabetes, Type 1, Plaque Psoriasis, Amevive, Alefacept

Experimental Psoriasis Drug Shows Promise

Posted 8 Jul 2015 by

WEDNESDAY, July 8, 2015 – Preliminary trial results suggest that an experimental psoriasis drug may control the chronic skin disease better than the current standard treatment. The drug, guselkumab, was compared to the commonly used medication adalimumab (Humira, Enbrel) in a study involving nearly 300 patients with plaque psoriasis. Up to 86 percent of patients who received guselkumab cleared their psoriasis or had minimal psoriasis after 16 weeks of treatment, compared to 58 percent of patients taking adalimumab, the researchers reported. However, patients getting guselkumab were somewhat more prone to infections, the researchers said. "As a dermatologist, I am particularly excited about the potential of guselkumab and what this investigational therapy may mean for patients and the treatment of moderate to severe plaque psoriasis in the future," said lead researcher Dr. Kristian ... Read more

Related support groups: Humira, Psoriasis, Plaque Psoriasis, Adalimumab

New Drug Shows Promise Against Psoriasis

Posted 16 Jun 2015 by

TUESDAY, June 16, 2015 – Many patients with the skin disease psoriasis showed significant improvement when taking an experimental drug called ixekizumab, according to a late-stage, phase 3 clinical trial. "The visible effects of psoriasis can have a major and life-ruining impact on people's confidence and self-esteem," study leader Chris Griffiths, a professor of dermatology at the University of Manchester in England, said in a university news release. "What we saw in this trial was not just the physical aspects of the disease clearing up, but people on the new drug also reporting a marked improvement in their quality of life as they felt more confident and suffered less from itching – far more than in the other two groups," he said. The trial was funded by drug maker Eli Lilly and included 2,500 patients with moderate-to-severe psoriasis. Half took ixekizumab, while the other half ... Read more

Related support groups: Psoriasis, Plaque Psoriasis

Injuries Up Risk of Psoriatic Arthritis for People With Psoriasis

Posted 12 Jun 2015 by

FRIDAY, June 12, 2015 – Injuries increase the risk of psoriatic arthritis in people who have psoriasis, a new study suggests. Psoriatic arthritis – chronic arthritis associated with the skin condition psoriasis – can lead to severe, disabling joint damage. About 30 percent of people with psoriasis develop psoriatic arthritis, according to the researchers. The study included information collected between 1995 and 2013. The information was from more than 70,000 psoriasis patients, including more than 15,000 who suffered physical injury. During that time, more than 1,000 cases of psoriatic arthritis were diagnosed. The incidence rate of psoriatic arthritis was 30 per 10,000 person-years among those who had a physical injury. In people without injury, the rate of psoriatic arthritis was 22 per 10,000 person-years. The increased risk of psoriatic arthritis associated with injury was even ... Read more

Related support groups: Psoriasis, Psoriatic Arthritis

Ingredient in MS, Psoriasis Drugs Linked to Two Deadly Brain Infections

Posted 9 Apr 2015 by

WEDNESDAY, April 8, 2015 – An active ingredient in some psoriasis and multiple sclerosis medications has been linked to two cases of a rare and sometimes lethal brain infection. The ingredient, dimethyl fumarate, appears to have contributed to the deaths of two European women. The women contracted progressive multifocal leukoencephalopathy, or PML, according to two letters published in the April 9 issue of the New England Journal of Medicine. One case involved a 54-year-old woman with multiple sclerosis. She died in October 2014 from complications related to PML and pneumonia, following 4.5 years of treatment with a time-delayed form of dimethyl fumarate carrying the brand name Tecfidera, researchers reported. The second case was a 64-year-old woman with psoriasis. She died in August 2014 from PML after being treated with a delayed-release dimethyl fumarate compound with the brand name ... Read more

Related support groups: Multiple Sclerosis, Psoriasis, Tecfidera, Dimethyl Fumarate

Health Tip: Spot the Symptoms of Scalp Psoriasis

Posted 11 Mar 2015 by

-- Scalp psoriasis may be confused with dandruff, but the two conditions can cause a host of differing symptoms. The American Academy of Dermatology says unique signs of scalp psoriasis may include: Patches of skin on the scalp that may be thick and inflamed. Bleeding from scratching the scalp. Extreme tenderness or a burning sensation on the scalp. Temporary hair loss. Read more

Related support groups: Psoriasis

New Psoriasis Drug Cosentyx Approved

Posted 21 Jan 2015 by

WEDNESDAY, Jan. 21, 2015 – The anti-psoriasis drug Cosentyx (secukinumab) has been approved by the U.S. Food and Drug Administration. Psoriasis in an immune system disorder that causes red, scaly patches of skin. It occurs most often in people aged 15 to 35, and among those with a family history of the disease, the agency said Wednesday in a news release. Cosentyx's active ingredient is a human antibody that inhibits a protein involved in inflammation. The injected drug's safety and effectiveness were evaluated in clinical studies involving more than 2,400 people with plaque psoriasis. The drug was found to clear psoriasis plaques from skin significantly better than a placebo, the FDA said. Since the drug affects the immune system, users may be at greater risk of infection. Serious allergic reactions to Cosentyx also are possible, the FDA warned. The drug's most common side effects are ... Read more

Related support groups: Psoriasis, Plaque Psoriasis

FDA Approves Cosentyx (secukinumab) for Plaque Psoriasis

Posted 21 Jan 2015 by

January 21, 2015 – The U.S. Food and Drug Administration today approved Cosentyx (secukinumab) to treat adults with moderate-to-severe plaque psoriasis. Psoriasis is a skin condition that causes patches of skin redness and irritation. Psoriasis is an autoimmune disorder, and occurs more commonly in patients in with a family history of the disease, and most often begins in people between the ages of 15 and 35. The most common form of psoriasis is plaque psoriasis, in which patients develop thick, red skin with flaky, silver-white patches called scales. Cosentyx’s active ingredient is secukinumab. Secukinumab is an antibody that binds to a protein (interleukin (IL)-17A) which is involved in inflammation. By binding to IL-17A, secukinumab prevents it from binding to its receptor, and inhibits its ability to trigger the inflammatory response that plays a role in the development of p ... Read more

Related support groups: Psoriasis, Plaque Psoriasis

Psoriasis Costs Americans Up to $135 Billion Annually, Study Finds

Posted 8 Jan 2015 by

WEDNESDAY, Jan. 7, 2015 – Psoriasis is more than just a troublesome skin condition for millions of Americans – it also causes up to $135 billion a year in direct and indirect costs, a new study shows. According to data included in the study, about 3.2 percent of the U.S. population has the chronic inflammatory skin condition. "Psoriasis patients may endure skin and joint disease, as well as associated conditions such as heart disease and depression," said Dr. Amit Garg, a dermatologist at North Shore-LIJ Health System in Manhasset, N.Y. "These patients may bear significant long-term costs related to the medical condition itself, loss of work productivity, as well as to intangibles such as restriction in activities and poor self-image, for example," he added. In the new study, a team led by Dr. Elizabeth Brezinski of the University of California, Davis reviewed 22 studies to estimate ... Read more

Related support groups: Psoriasis

Psoriasis Tied to Raised Risk of Uncontrolled Blood Pressure

Posted 15 Oct 2014 by

WEDNESDAY, Oct. 15, 2014 – People with more severe cases of psoriasis may be at increased risk of uncontrolled high blood pressure, a large study finds. Researchers looking at over 13,000 adults in the United Kingdom found that those with severe psoriasis were 48 percent more likely to have poorly controlled blood pressure, versus people without the skin condition. The findings, reported online Oct. 15 in the journal JAMA Dermatology, confirm an association between psoriasis and cardiovascular health. But the precise reasons are not clear, and a cause-and-effect link was not proven. "We still don't fully understand why we see a higher prevalence of cardiovascular risk factors in people with psoriasis," said study leader Dr. Junko Takeshita, a clinical instructor of dermatology at the University of Pennsylvania in Philadelphia. But, Takeshita said, chronic inflammation could be a common ... Read more

Related support groups: High Blood Pressure, Hypertension, Psoriasis

FDA Approves Otezla (apremilast) for Moderate to Severe Plaque Psoriasis

Posted 23 Sep 2014 by

SUMMIT, N.J.--(BUSINESS WIRE)-- Celgene Corporation today announced that the U.S. Food and Drug Administration (FDA) has approved Otezla (apremilast), the Company's oral, selective inhibitor of phosphodiesterase 4 (PDE4), for the treatment of patients with moderate to severe plaque psoriasis for whom phototherapy or systemic therapy is appropriate. Otezla is the first and only PDE4 inhibitor approved for the treatment of plaque psoriasis. Psoriasis, a chronic inflammatory disease of the skin resulting from an uncontrolled immune response, affects more than 125 million people worldwide. "Otezla offers an important new treatment option for patients whose symptoms are not adequately improving with their current treatments. In clinical trials, Otezla reduced redness, thickness, and scaliness of plaques in patients with moderate or severe plaque psoriasis," said Dr. M. Shane Chapman, ... Read more

Related support groups: Psoriasis, Plaque Psoriasis, Otezla, Apremilast

Psoriasis Treatment Choices Improving, FDA Says

Posted 5 Sep 2014 by

FRIDAY, Sept. 5, 2014 – A growing knowledge of the skin disease called psoriasis is leading to greater treatment choices, including personalized therapies, the U.S. Food and Drug Administration reports. Psoriasis is an immune system disorder that causes overproduction of skin cells, resulting in scaling, pain, swelling, redness and heat. The condition affects about 7.5 million Americans. "As we better understand the disease, researchers know more about what specific factors to target in order to develop effective treatments," FDA dermatologist Dr. Melinda McCord said in an agency news release. There is no cure for psoriasis, so the main goals of treatments are to stop skin cell overproduction and reduce inflammation. Current therapies include medicines applied to the skin (topical), light treatment (phototherapy), or drugs taken by mouth or given by injection. Doctors used to take a ... Read more

Related support groups: Psoriasis

FDA Approves Rasuvo (methotrexate) Injection

Posted 14 Jul 2014 by

Chicago, IL, July 14, 2014 – Medac Pharma, Inc., a privately held pharmaceutical company focused on the development of new molecules and improving the effectiveness of existing medicines, announced that the U.S. Food and Drug Administration (FDA) has approved Rasuvo, a subcutaneous injectable methotrexate (MTX) therapy delivered in an auto-injector for rheumatoid arthritis (RA), polyarticular-course juvenile idiopathic arthritis (pJIA) and psoriasis. Rasuvo will be available in 10 dosage strengths, ranging from 7.5 mg to 30 mg in 2.5 mg increments and will be launched in the U.S. The company concurrently announced that the U.S. District Court for the District of Delaware has denied a motion for a preliminary injunction filed by Antares Pharma, Inc. “We’re delighted to have secured approval for our lead product, Rasuvo, and look forward to introducing this much-needed therapy to the ma ... Read more

Related support groups: Rheumatoid Arthritis, Methotrexate, Psoriasis, Juvenile Idiopathic Arthritis

New Psoriasis Drug Shows Promise in Trials

Posted 10 Jul 2014 by

WEDNESDAY, July 9, 2014 – A new psoriasis drug delivered dramatic results in two clinical trials, perhaps heralding an effective new treatment for patients with the chronic skin disease. The drug, secukinumab, was stacked up against an inactive placebo and one of the best psoriasis medications on the market. "Over a quarter of patients have not a dot of psoriasis left," said study co-author Dr. Mark Lebwohl, chairman of dermatology at the Icahn School of Medicine at Mount Sinai in New York City. "Over half the patients have a 90 percent improvement in their psoriasis, and that means there's hardly any psoriasis left. This kind of data is better than anything we've seen in the past," he added. The study results were published online July 9 in the New England Journal of Medicine. Psoriasis causes overproduction of skin cells, which results in thick red marks and flaky white lesions that ... Read more

Related support groups: Psoriasis

Page 1 2 3 4 5 Next

Ask a Question

Further Information

Related Condition Support Groups

Plaque Psoriasis, Psoriatic Arthropathy, Dermatological Disorders

Related Drug Support Groups

prednisone, methotrexate, Humira, methylprednisolone, Remicade, dexamethasone, triamcinolone, clobetasol, Therapeutic, view more... fluocinonide, Kenalog, Clobex, cyclosporine, desonide, Stelara, desoximetasone, hydroxyurea, Elocon, Topicort, Soriatane, Dovonex, Lidex, Tazorac, Psoriasin, infliximab, Kenalog-40, Cordran, Olux, coal tar, Kenalog-10, Halog, acitretin, Acth, Cordran Tape, Acthar, Cloderm, calcipotriene, Cortizone-10, Neoral, feverfew, etanercept, Vanos, Locoid, Taclonex, Analpram-HC, Dermovate, halobetasol, Olux-E, Eczema Cream, Temovate, Deltasone, alclometasone, adalimumab, halcinonide, methoxsalen, Ultravate, Cortaid, Acthar Gel, HP, Anucort-HC, ustekinumab, tazarotene, resorcinol, Linotar, Proctofoam HC, Linotar Gel 2, Vectical, Cyclocort, Dritho-Scalp, Gengraf, betamethasone / calcipotriene, Aristocort A, Locoid Lipocream, anthralin, Sterapred, Verdeso, Corticaine, Sterapred DS, Liquid Pred, Soriatane CK, Pandel, Proctozone HC, Cortaid Maximum Strength, Instacort 10, Cortizone-10 Plus, DHS Tar Shampoo, Doak Tar Oil, Dermarest Dricort, Neutrogena T / Derm, Zone-A, Aquanil HC, Taclonex Scalp, Doak Oil Forte, Desonate, Linotar Gel 3, Coal Tar Strong, Hycort, Aristocort R, Triderm, Oxsoralen-Ultra, Drithocreme, Anti-Dandruff, Trianex, DesOwen, Topicort LP, hydrocortisone / pramoxine, Halog-E, Zithranol, Doak Tar, Psoriatec, Embeline, Cortane, Fototar, Hemorrhoidal HC, corticotropin, diflorasone, X-Seb T Plus, Instacort, Nutracort, Trexall, Aristospan, Aclovate, Hytone, Pramosone, Dermatop, Methotrexate LPF Sodium, Scalp-Cort, Nupercainal HC 1%, Hydrocort cream, Ala-Scalp HP, Ivocort, Cotacort, Genasone / Aloe, Proctocream-HC, Lacticare-HC, Ala-Cort, Penecort, Beta HC, Nogenic HC, Acticort 100, Dermolate, Cortaid with Aloe, Dermol HC, Delcort, Caldecort, Corticreme, Gly-Cort, Anurx-HC, Rederm, Sarnol-HC, Scalp-Aid, Recort Plus, Aloe Cort, Anutone-HC, Hi-Cor, Cort-Dome, Zithranol-RR, Sorilux, Pramosone E, Calcitrene, HC Pram, Anthraforte, Halonate, Ala-Scalp, Hydrocortisone 1% In Absorbase, Scalacort, Analpram E, Cormax Scalp, Hemril-HC Uniserts, Anthrascalp, Pediaderm TA, Clodan, Rasuvo, Halac, MG217 Psoriasis, Tarsum, Otrexup, Keratol HC, Pediaderm HC, Carb-O-Lac HP, Carb-O-Lac5, Carmol HC, Fluocinonide-E, MD Hydrocortisone, Proctosert HC, Proctozone-H, U-Cort, Cortaid Intensive Therapy, Encort, Hemril-30, Anuzone HC, Cortizone-5, Cortizone for Kids, Neutrogena T-Scalp, Dermtex HC, NuZon, Gynecort Maximum Strength, PC Tar, Ultravate PAC, Dermagesic, Resinol, Scytera, Temovate E, OraMagic Rx, Procto-Pak 1%, Itch-X Lotion, Z-Xtra, Olux / Olux-E Kit, Dermarest Plus Anti-Itch, Theraplex T, Delonide, Clobevate, Florone, Psorcon, Florone E, Embeline E, Cormax, Anthra-Derm, Clinacort, Micanol, A-Fil, Temovate Emollient, Psorcon E, ApexiCon E, Rx Triamcinolone, Flutex, Cinalog, Cinolar, Enzone, Delta-Tritex, Aricin, Licon, Dermacin, Fluex, Triacet, Prednicot, Prednicen-M, ammonium lactate / halobetasol, benzocaine / pyrilamine / zinc oxide, MG217 Medicated Tar, Medotar, Ionil T, prednicarbate, flurandrenolide, amcinonide, ammonium lactate / urea, clocortolone, coal tar / salicylic acid, Tridesilon, LoKara, 8-MOP, Scalpicin, Folex PFS, Meticorten, Orasone, ProctoCare-HC, Epifoam, Apexicon, Maxiflor, Lidex-E, Cordran SP, Zone-A Forte, Rectocort HC, R A Acne, Pinetarsol Tar, Dovobet, Utralytic, Ultralytic 2, Apha Keri Tar Gel, Orion Coal Tar, Alphosyl, Alphosyl 2 in 1, Carbo-Dome, Apha Keri Tar, Ultralytic, Cort-Dome High Potency, Procto-Kit 2.5%, Proctocort, Proctosol-HC, Anuprep-HC, Rectasol-HC, Procto-Kit 1%, Texacort, Cetacort, Dermacort, Westcort, Aeroseb-HC, Clinitar, Psoriderm, Neutrogena T / Gel, Ionil T Plus, Tegrin Medicated, Pentrax, Estar, Zeprime Tar Emulsion, G-TAR, Novacort, Hydropram, HC Pramoxine, Zetar, Balnetar, Betatar Gel, Elta Tar, Cutar, Reme-T, Exorex, Polytar Mild, Doctar, Polytar, Oxipor VHC, Pentrax Gold, Tegrin Medicated Soap, Psorigel, Anumed-HC